New CRISPR Gene-Editing Treatment Approved In Europe For Inherited Blood Disorders

The decision comes after Vertex Pharmaceuticals and CRISPR Therapeutics ’ Casgevy was approved in the UK and US for sickle cell disease and beta thalassemia.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Business /business Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news topline Source Type: news